WG5 - Promote dissemination
OverviewSEEK ID: https://fairdomhub.org/projects/312
Public web page: Not specified
Organisms: No Organisms specified
FAIRDOM PALs: No PALs for this Project
Project created: 24th Oct 2022
Related items
Projects: de.NBI-SysBio, Kinetics on the move - Workshop 2016, Example use cases, SBEpo - Systems Biology of Erythropoietin, FAIRDOM & LiSyM & de.NBI Data Structuring Training, FAIRDOM, EnzymeML, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik", FAIRDOM Community Workers, MIX-UP, COVID-19 Disease Map, ERNEST Mapping Group Pilot Study, NMTrypI - New Medicines for Trypanosomatidic Infections, Standardization of enzyme-catalyzed reaction measurement, Standardization of enzyme-catalyzed reaction modelling, ModeleXchange initiative, CoVIDD - Coronavirus interactions in drug discovery - optimization and implementation, Mass spectrometry proteomics for biomarker discovery, Thymidylate synthase dimer dissociation, WG1 - Compound libraries coordination and integration of compound design, WG2 - Integration of early phase studies and low environmental impact actions, WG3 - Coordination of in vitro-to-in vivo translation of OneHealth leads and candidates, WG4 - Integration of R&D process-environmental studies and translation in informed whitepaper, WG5 - Promote dissemination, WG6 - Promote the transfer of knowledge, SABIO-VIS
Institutions: Heidelberg Institute for Theoretical Studies (HITS gGmbH)
https://orcid.org/0000-0002-9077-5664
The recent COVID19 pandemic infection has undisclosed long-standing issues in the translation of drugs from animals to humans or vice-versa. Nearly 75% of emerging human infections worldwide originated from animals; existing drugs for human and animal (H&A) vector-borne diseases (VBD) are scarce, with limited efficacy, toxicity, and finite resources. Emerging environmental problems in pharmaceutical use/manufacturing increase attention in the field. The two drug pipelines are developed ...
Projects: WG1 - Compound libraries coordination and integration of compound design, WG2 - Integration of early phase studies and low environmental impact actions, WG3 - Coordination of in vitro-to-in vivo translation of OneHealth leads and candidates, WG4 - Integration of R&D process-environmental studies and translation in informed whitepaper, WG5 - Promote dissemination, WG6 - Promote the transfer of knowledge
Web page: Not specified
